TGTX TG Therapeutics, Inc.
Price Chart
Executive Summary
TG Therapeutics published a post-hoc pooled analysis of Phase 3 ULTIMATE I/II data in Frontiers in Immunology, showing BRIUMVI (ublituximab) reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve RMS patients, with 82.7% achieving NEDA-3 vs. 23.1% for teriflunomide. This is a positive clinical data publication reinforcing BRIUMVI's efficacy in early-stage patients, but it is not a new regulatory event or commercial catalyst — it adds to the existing evidence base without changing the approved label or near-term revenue trajectory.
Actionable Insight
This publication strengthens BRIUMVI's clinical profile for early-use high-efficacy therapy, which could support formulary positioning and physician adoption. Monitor upcoming quarterly earnings for prescription trends and any label expansion updates. The data is incremental — not a binary catalyst — so expect modest positive sentiment rather than a major re-rating.
Key Facts
- BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients (0.081 vs. 0.188; p<0.001)
- In treatment-naïve patients treated within 3 years of symptom onset, ARR reduction was 61.0% (0.130 vs. 0.334; p=0.004)
- 2-fold greater confirmed disability improvement (CDI) in treatment-naïve patients (10.7% vs. 5.3%; p=0.010); 4-fold greater CDI in early-treated patients (14.4% vs. 3.6%; p=0.002)
- Ublituximab reduced gadolinium-enhancing T1 lesions by 96.1% and new/enlarging T2 lesions by 90.6% vs. teriflunomide (p<0.001 for both)
- 82.7% of treatment-naïve ublituximab patients achieved NEDA-3 vs. 23.1% for teriflunomide (3.6-fold higher; p<0.001)
- Data published in Frontiers in Immunology, a peer-reviewed journal
Financial Impact
No new financial figures provided; publication supports BRIUMVI's clinical differentiation, which may support continued market share growth in the ~$20B+ RMS market, but no revenue or guidance changes were announced.
Risk Factors
- No new regulatory or commercial catalyst — data is a post-hoc analysis, not a prospective trial
- BRIUMVI faces competition from established high-efficacy therapies (Ocrevus, Kesimpta, Tysabri) with longer track records
- Forward-looking statements caution that prescription trends and revenue targets may not be sustained
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304240 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
5d ago
|
Institutional Cluster
| $49.52 $50.30 | ▲ +1.58% | ▼ −0.19% | $50.54 (+2.06%) |
|
Jun 3, 2026
13d ago
|
8-K
| $40.11 $40.56 | ▲ +1.12% | ▲ +0.72% | $50.54 (+26.00%) |
|
Jun 3, 2026
13d ago
|
Press Release
| $40.11 $40.56 | ▲ +1.12% | ▲ +0.72% | $50.54 (+26.00%) |
|
Jun 1, 2026
15d ago
|
Press Release
| $37.41 $36.64 | ▼ −2.06% | ▼ −2.20% | $50.54 (+35.10%) |
|
May 27, 2026
20d ago
|
8-K
| $38.82 $37.94 | ▼ −2.27% | ▼ −2.51% | $50.54 (+30.19%) |
|
May 6, 2026
5w ago
|
8-K
| $41.97 $43.03 | ▲ +2.51% | ▲ +2.84% | $50.54 (+20.42%) |
|
Apr 30, 2026
6w ago
|
Press Release
| $33.78 $33.85 | ▲ +0.21% | ▼ −0.01% | $50.54 (+49.62%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $38.31 $36.92 | ▼ −3.63% | ▼ −3.23% | $50.54 (+31.92%) |
|
Apr 15, 2026
8w ago
|
Press Release
| $34.60 $34.30 | ▼ −0.87% | ▼ −1.12% | $50.54 (+46.07%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $30.36 $30.07 | ▼ −0.96% | ▲ +0.79% | $50.54 (+66.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access